BackMineralys Therapeutics Overview

Mineralys Therapeutics Current Cash

Mineralys Therapeutics's current cash is $110M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$112.78M
↓ 31.65% YoYΔ $-52.23M vs prior year quarter

Peer average

Loading

Mineralys Therapeutics Current Cash History

Loading

Mineralys Therapeutics vs. peers: Current Cash Comparison

Loading

Mineralys Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Mineralys Therapeutics (MLYS) FAQ

Mineralys Therapeutics posts a current cash of $110M as of March 2026. That compares with $170M in the prior-year period — down 31.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Mineralys Therapeutics's current cash was $170M. The latest reading is $110M — a 31.7% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of Mineralys Therapeutics's financial statement story. At $110M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for MLYS's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Mineralys Therapeutics's other metric pages and overview cover the third.